Latest Ratios: P/E Ratio -7.1x · EV/EBITDA N/A · ROE -143.6%. (2002–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $173M | $209M | $194M | $141M | $157M | $468M | $370M | $334M | $56M | $18M | $14M |
| Enterprise Value | $165M | $201M | $188M | $127M | $155M | $436M | $331M | $308M | $46M | $14M | $6M |
| P/E Ratio → | -7.08 | — | — | — | — | — | — | — | 491.36 | — | — |
| P/S Ratio | 5.34 | 6.46 | 7.22 | 5.28 | 5.59 | 13.38 | 13.90 | 11.54 | 1.92 | 0.58 | 0.44 |
| P/B Ratio | 8.60 | 11.17 | 16.99 | 6.44 | 4.93 | 11.88 | 9.20 | 11.69 | 7.74 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.21 | 6.98 | 4.74 | 5.50 | 12.44 | 12.42 | 10.65 | 1.55 | 0.46 | 0.18 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.7% | 52.7% | 54.2% | 55.5% | 65.6% | 66.3% | 71.2% | 78.8% | 80.5% | 65.5% | 76.6% |
| Operating Margin | -68.3% | -68.3% | -91.9% | -81.6% | -66.7% | -36.8% | -25.2% | -16.7% | -8.4% | -19.0% | -20.0% |
| Net Profit Margin | -66.8% | -66.8% | -89.3% | -77.4% | -65.0% | -30.6% | -25.0% | -15.9% | 0.4% | -18.9% | -16.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -143.6% | -143.6% | -144.2% | -76.9% | -51.3% | -26.9% | -19.3% | -25.7% | 1.6% | — | — |
| ROA | -43.7% | -43.7% | -54.3% | -43.5% | -32.0% | -18.4% | -13.4% | -14.8% | 0.8% | -37.2% | -26.3% |
| ROIC | -207.9% | -207.9% | -289.6% | -89.0% | -78.2% | -256.7% | -294.8% | — | — | — | — |
| ROCE | -80.4% | -80.4% | -92.0% | -64.4% | -43.2% | -28.8% | -18.3% | -24.3% | -29.5% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.29 | 0.29 | 0.53 | 0.25 | 0.18 | 0.15 | 0.11 | 0.15 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.43 | -0.54 | -0.65 | -0.09 | -0.83 | -0.98 | -0.91 | -1.48 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -1279.71 | — | — | -148.32 | -32.92 | -2.59 |
Net cash position: cash ($13M) exceeds total debt ($5M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.51 | 1.51 | 1.22 | 2.51 | 3.03 | 3.87 | 3.88 | 3.19 | 1.76 | 0.33 | 0.54 |
| Quick Ratio | 1.09 | 1.09 | 0.84 | 1.88 | 2.47 | 3.54 | 3.64 | 3.04 | 1.65 | 0.29 | 0.39 |
| Cash Ratio | 0.60 | 0.60 | 0.57 | 1.50 | 1.99 | 2.92 | 3.24 | 2.48 | 1.06 | 0.12 | 0.24 |
| Asset Turnover | — | 0.62 | 0.58 | 0.64 | 0.53 | 0.57 | 0.48 | 0.66 | 1.59 | 2.92 | 1.53 |
| Inventory Turnover | 1.60 | 1.60 | 1.48 | 1.41 | 1.23 | 2.66 | 2.33 | 3.32 | 4.80 | 9.38 | 1.40 |
| Days Sales Outstanding | — | 65.92 | 51.85 | 52.11 | 66.01 | 56.34 | 48.18 | 67.31 | 62.45 | 50.25 | 52.95 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | 0.2% | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $91M | $85M | $81M | $76M | $76M | $73M | $63M | $52M | $23M | $22M |
Liquidity and capital runway
Based on recent financial data, Stereotaxis trades at a price-to-sales multiple of 5.07, a valuation that appears to price in significant future growth potential despite the company's persistent inability to generate positive earnings or cash flow in the current competitive medical device landscape.
The current P/S multiple suggests that investors are valuing the firm as a high-growth robotic platform rather than a traditional medical device manufacturer. This valuation appears disconnected from the company's historical inability to achieve GAAP profitability, implying that the market is heavily discounting the risk of further dilutive capital raises.
According to quarterly filings, Stereotaxis has consistently reported negative ROIC, with figures reaching as low as -102.6% in 2025Q1, indicating that the company is currently failing to generate any meaningful return on the capital deployed into its Genesis robotic system and associated infrastructure.
The deeply negative ROIC trend suggests that the company's core business model is currently value-destructive rather than compounding. Investors should monitor whether the shift toward proprietary catheters can improve capital efficiency, as the current returns remain well below the cost of capital for any comparable medical technology firm.
As reported in recent financial statements, the company's cash conversion cycle remains highly volatile, peaking at 299 days in 2026Q1, which reflects significant challenges in managing inventory levels and collecting receivables relative to the slow-moving sales cycle of its high-value robotic capital equipment.
The elevated days inventory outstanding, which reached 362 days in 2026Q1, suggests that the company is carrying substantial hardware inventory that is not turning over quickly enough to support a lean operating model. This inefficiency ties up critical cash resources, exacerbating the company's reliance on external financing to fund its ongoing operations.
Investors frequently misapply price-to-sales multiples to Stereotaxis, which obscures the underlying reality that the company's revenue is heavily weighted toward lumpy, low-margin capital equipment sales rather than the high-margin, recurring disposable revenue streams that typically justify premium valuation multiples in the medical device sector.
Using P/S as a primary valuation tool ignores the structural margin constraints and the high cost of customer acquisition inherent in the robotic EP space. A more appropriate metric would be an adjusted EV/Gross Profit or a focus on the 'attach rate' of proprietary disposables, which would better reflect the company's true potential for long-term earnings power.
Includes 30+ ratios · 24 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying STXS stock.
Stereotaxis, Inc.'s current P/E ratio is -7.1x. This places it at the 50th percentile of its historical range.
Stereotaxis, Inc.'s return on equity (ROE) is -143.6%. The historical average is -123.7%.
Based on historical data, Stereotaxis, Inc. is trading at a P/E of -7.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Stereotaxis, Inc. has 52.7% gross margin and -68.3% operating margin.